BridgeBio Pharma Inc BBIO.OQ BBIO.O is expected to show a rise in quarterly revenue when it reports results on February 24 for the period ending December 31 2025
The Palo Alto California-based company is expected to report a 2,396.5% increase in revenue to $146.844 million from $5.88 million a year ago, according to the mean estimate from 16 analysts, based on LSEG data.
LSEG's mean analyst estimate for BridgeBio Pharma Inc is for a loss of 74 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 22 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for BridgeBio Pharma Inc is $96.00, about 35.7% above its last closing price of $70.72
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.88 | -0.89 | -0.95 | Missed | -6.9 |
Jun. 30 2025 | -0.76 | -0.84 | -0.95 | Missed | -12.6 |
Mar. 31 2025 | -0.92 | -0.92 | -0.88 | Beat | 4.7 |
Dec. 31 2024 | -1.17 | -1.13 | -1.40 | Missed | -23.8 |
Sep. 30 2024 | -0.92 | -0.98 | -1.10 | Missed | -12.4 |
Jun. 30 2024 | -1.07 | -1.06 | -0.39 | Beat | 63.3 |
Mar. 31 2024 | -0.87 | -0.76 | -0.20 | Beat | 73.8 |
Dec. 31 2023 | -0.90 | -0.91 | -0.96 | Missed | -5.4 |
This summary was machine generated February 20 at 22:26 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)